IN THIS ISSUE
Highlighted research articles .................................. 2945

NEWS IN BRIEF
Important news stories affecting the community ........ 2950

RESEARCH WATCH
Selected highlights of recent articles of exceptional significance from the cancer literature ................. 2955

ONLINE
For more News and Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

VIEWS
In the Spotlight
For Whom the Bell Tolls? A Toll-Like Receptor 9 Agonist’s Journey from Vaccine Adjuvant to Promising Agent in Anti–PD-1–Resistant Melanoma ........................ 2960
R.J. Sullivan
See article, p. 2998

A Tale of Two Histologies: Dissecting the Biology of Lineage Transformation in Lung Cancer .......................... 2962
C.B. Meador and C.M. Lovly
See article, p. 3028

Harnessing Mitochondrial Mutations to ATAC Clonal Evolution in CLL .................................. 2965
L.K. Hilton and D.W. Scott
See article, p. 3048

REVIEWS
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease .... 2968
E.J. Moding, B.Y. Nabet, A.A. Alizadeh, and M. Diehn

Clonal Hematopoiesis: From Mechanisms to Clinical Intervention .......................... 2987
T. Köhnke and R. Majeti

RESEARCH BRIEF
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma ....... 2998
Précis: Intratumoral vidutolimod (CpG-A TLR9 agonist) together with pembrolizumab overcomes PD-1 blockade resistance in 25% of patients with metastatic melanoma with manageable toxicities in a phase I trial.
See commentary, p. 2960

RESEARCH ARTICLES
Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing .... 3008
Précis: Analysis of data from the Genomes for Kids research study reveals the value of three-platform whole-genome, whole-exome, and RNA sequencing in identifying clinically and biologically relevant lesions in pediatric cancer.

Multimomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation ............ 3028
resulting in induction of the interferon pathway through derepression of ERVs and dsRNA stress, potentiates anticancer immune surveillance of AURKB, leading to induction of G2/M arrest, repression of AKT signaling and destabilization of Aurora Kinase B, leading to induction of G2/M arrest, repression of AKT signaling and destabilization of Aurora Kinase B.

Precis: Integrative multi-omic approaches revealed pathways dysregulated upon neuroendocrine transformation and nominated the PI3K/AKT pathway as a therapeutic target to inhibit transformation in EGFR-mutant lung adenocarcinoma.

See commentary, p. 2962

Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History ...................... 3048


Precis: Single-cell analysis of serial chronic lymphocytic leukemia (CLL) samples highlights the potential of mitochondrial DNA mutations as natural barcodes, and, along with chromatin accessibility and CNV changes, reveals insight into the clonal evolution of CLL.

See commentary, p. 2965

AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway-Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B .......... 3064


Precis: AKT depletion using a degrader proved superior to kinase inhibition due to sustained repression of AKT signaling and destabilization of AURKB, leading to induction of G2/M arrest, hyperploidy, and cell death.

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity .......... 3090


Precis: Reactivation of p53 by MDM2 inhibitors potentiates anticancer immune surveillance through derepression of ERVs and dsRNA stress, resulting in induction of the interferon pathway and improved response to checkpoint therapy.

Cholesterol Auxotrophy as a Targetable Vulnerability in Clear Cell Renal Cell Carcinoma .................. 3106


Precis: Multi-omic analyses of clear cell renal cell carcinoma revealed a strict exogenous cholesterol dependency as a novel therapeutic strategy by limiting cholesterol availability and/or inhibiting a key cholesterol transporter.

A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms ......................... 3126


Precis: A patient-derived xenograft system was developed that enables engraftment of primary cells from patients with myelofibrosis (MF) and transmission of phenotypes, such as bone marrow fibrosis, and genotypes including MF driver mutations in mice with expression of human myeloid promoting cytokines.

Tumor Microenvironment-Derived R-spondins Enhance Antitumor Immunity to Suppress Tumor Growth and Sensitize for Immune Checkpoint Blockade Therapy .................. 3142


Precis: Bioinformatic analysis coupled with in vivo studies identified R-spondins as immunotherapeutic modulators in tumors that enhanced natural killer cell and CD8+ T-cell antitumor immunity, inhibited tumor progression, and sensitized cells to anti–PD-1 therapy.

Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrareplicative Biliary Cancer .................. 3158

M. Reichert, W. Weichert, O.J. Sansom, J.P. Morton, R. Rad, G. Schneider, and D. Saur

**Précis:** Genetic screening in a mouse model of biliary cancer revealed Pik3cdR1487G as critical for transformation and tumor formation and additionally reveals the context- and tissue-specific nature of oncogenic drivers.

**Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4⁺ T Cells That Subvert Immunosuppression** …… 3178

S.-C.A. Lai, H. Gundlapalli, H.A. Ekiz, A. Jiang, E. Fernandez, and A.L. WelM

**Précis:** Inhibition of a specific isoform of RON receptor tyrosine kinase (SF-RON) recruits stem-like CD4 T cells to the metastatic site and promotes strong antitumor immune responses that severely restrict growth of breast cancer metastases.

**Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy ............ 3198**


**Précis:** Oncogenic NPM1c mutations prime acute myeloid leukemia cells for mitochondrial targeting by actinomycin D, which restores PML nuclear bodies—driven senescence and is synergistic with venetoclax to induce tumor clearance.

**Rif–Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer ............... 3214**


**Précis:** The first genetically engineered mouse model expressing the Rif–MycI fusion protein indicated the ability of this fusion to promote transformation and tumorigenesis of small cell lung cancer as well as increase metastatic potential to an array of different sites.

---

**ON THE COVER**

In addition to its tumor suppressor gene function, p53 has been shown to contribute to silencing of repetitive elements including endogenous retrovirus (ERV) long terminal repeat sequences. Zhou, Singh, and colleagues made the unexpected observation that upon p53 activation through pharmacologic inhibition of its negative regulator MDM2, ERV expression was increased due to increased p53 occupancy on ERV promoters and p53-mediated suppression of LSD1 and DNMT1, two major ERV represors. ERV derepression following MDM2 inhibition contributed to double-stranded RNA stress leading to type I/III interferon (IFN) expression, antigen processing/presentation, and increased T-cell infiltration. Additionally, dual treatment with an anti-PD-1 antibody along with an MDM2 inhibitor markedly reduced tumor growth in a poorly immunogenic murine model of melanoma as compared with checkpoint therapy alone. An augmentation of IFN signaling and immune cell recruitment was also observed in patients who received an MDM2 inhibitor. For more information, see the article by Zhou, Singh, and colleagues on page 3090.

doi:10.1158/2159-8290.CD-11-12-CVR
CANCER DISCOVERY

11 (12)

*Cancer Discov* 2021;11:OF3-3229.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://cancerdiscovery.aacrjournals.org/content/11/12">http://cancerdiscovery.aacrjournals.org/content/11/12</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://cancerdiscovery.aacrjournals.org/content/11/12">http://cancerdiscovery.aacrjournals.org/content/11/12</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>